MX2013012526A - Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos. - Google Patents

Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.

Info

Publication number
MX2013012526A
MX2013012526A MX2013012526A MX2013012526A MX2013012526A MX 2013012526 A MX2013012526 A MX 2013012526A MX 2013012526 A MX2013012526 A MX 2013012526A MX 2013012526 A MX2013012526 A MX 2013012526A MX 2013012526 A MX2013012526 A MX 2013012526A
Authority
MX
Mexico
Prior art keywords
disease
methods
autism
huntington
disorders
Prior art date
Application number
MX2013012526A
Other languages
English (en)
Other versions
MX357761B (es
Inventor
Joseph Moskal
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of MX2013012526A publication Critical patent/MX2013012526A/es
Publication of MX357761B publication Critical patent/MX357761B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La descripción se refiere, por lo menos en parte, a métodos para tratar autismo en un paciente necesitado del mismo al administrar una cantidad terapéuticamente efectiva de un compuesto descrito, por ejemplo, un agonista parcial del sitio de glicina del receptor de NMDA.
MX2013012526A 2011-04-27 2012-04-27 Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos. MX357761B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161479593P 2011-04-27 2011-04-27
US201161527744P 2011-08-26 2011-08-26
PCT/US2012/035547 WO2012149389A2 (en) 2011-04-27 2012-04-27 Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders

Publications (2)

Publication Number Publication Date
MX2013012526A true MX2013012526A (es) 2014-04-16
MX357761B MX357761B (es) 2018-07-23

Family

ID=47073094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012526A MX357761B (es) 2011-04-27 2012-04-27 Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.

Country Status (13)

Country Link
US (4) US20140107037A1 (es)
EP (2) EP2701721A4 (es)
JP (1) JP6035326B2 (es)
KR (5) KR20190037359A (es)
CN (2) CN103974712A (es)
AU (1) AU2012249397B2 (es)
BR (1) BR112013027554A2 (es)
CA (1) CA2834286A1 (es)
EA (2) EA029999B1 (es)
HK (1) HK1258231A1 (es)
MX (1) MX357761B (es)
SG (2) SG194230A1 (es)
WO (1) WO2012149389A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033757A1 (en) 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
SG10201501050RA (en) 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
BR112015018092A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
JP2016506958A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
BR112015018094A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor nmda de espiro-lactama e usos dos mesmos
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
KR20160077153A (ko) 2013-10-28 2016-07-01 노렉스, 인크. Nmda 수용체 조절인자 및 이들의 전구약물, 염, 그리고 용도
CA2933372A1 (en) * 2013-12-13 2015-06-18 Northwestern University Methods of treating brain disorders or identifying biomarkers related thereto
CN105327349A (zh) * 2014-06-18 2016-02-17 上海翰森生物医药科技有限公司 Nmda受体拮抗剂的医药用途及其药物组合物
RU2721401C2 (ru) * 2014-06-23 2020-05-19 Нортвестерн Юниверсити Способы лечения или облегчения мигрени
EP3362080A1 (en) * 2015-10-16 2018-08-22 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
KR102128675B1 (ko) 2016-05-19 2020-06-30 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US11028095B2 (en) 2016-08-01 2021-06-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
EA201990428A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
JP2019527233A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
KR20200115611A (ko) 2018-01-31 2020-10-07 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
KR102415692B1 (ko) 2020-09-01 2022-07-05 건국대학교 글로컬산학협력단 시냅스 불균형 조절에 의한 발달장애 예방, 개선 또는 치료용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
GB0018272D0 (en) * 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
EP1471909A4 (en) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
ES2428313T3 (es) * 2005-03-24 2013-11-07 Emory University Métodos para el tratamiento de lesiones del sistema nervioso central mediante un protocolo de administración decreciente
US9783851B2 (en) * 2008-02-20 2017-10-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
WO2010033757A1 (en) * 2008-09-18 2010-03-25 Naurex, Inc. Nmda receptor modulators and uses thereof
PT2485751E (pt) * 2009-10-05 2014-09-01 Univ Northwestern Glyx-13 para uso num método para tratar depressão refratária

Also Published As

Publication number Publication date
SG194230A1 (en) 2013-12-30
US20210169964A1 (en) 2021-06-10
AU2012249397A1 (en) 2013-11-07
WO2012149389A2 (en) 2012-11-01
MX357761B (es) 2018-07-23
CN103974712A (zh) 2014-08-06
EP3679931A3 (en) 2020-10-14
EA201391581A1 (ru) 2014-05-30
US20140107037A1 (en) 2014-04-17
KR20190037359A (ko) 2019-04-05
JP6035326B2 (ja) 2016-11-30
EA029999B1 (ru) 2018-06-29
US20170049845A1 (en) 2017-02-23
EP2701721A2 (en) 2014-03-05
WO2012149389A3 (en) 2014-05-08
KR20180095096A (ko) 2018-08-24
KR20140043078A (ko) 2014-04-08
HK1258231A1 (zh) 2019-11-08
BR112013027554A2 (pt) 2016-09-06
AU2012249397B2 (en) 2017-03-30
KR20210046843A (ko) 2021-04-28
EA201790653A1 (ru) 2017-07-31
CN108283712A (zh) 2018-07-17
CA2834286A1 (en) 2012-11-01
KR20200043534A (ko) 2020-04-27
EP2701721A4 (en) 2015-12-16
SG10202010665YA (en) 2020-11-27
EP3679931A2 (en) 2020-07-15
JP2014520072A (ja) 2014-08-21
US20190209642A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
MX2013012526A (es) Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.
MY195289A (en) Anti IL-36R Antibodies
MX349950B (es) Profarmacos de treprostinil enlazados a un portador.
IN2014CN02616A (es)
MY202135A (en) Uses of neuroactive compounds
NZ716977A (en) Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2014004196A (es) Citramida de rasagilina.
MY180581A (en) A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
UA113750C2 (xx) Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону
MX344473B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
UA117032C2 (uk) Селективний інгібітор фосфатидилінозитол-3-кінази-гамма
MX348831B (es) Administración parenteral de tapentadol.
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
BR112015011798A2 (pt) métodos e composições para tratar doenças neurodegenerativas
EP2542085A4 (en) COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
MX367811B (es) D-metadona para el tratamiento de síntomas psiquiátricos.
CA2851761C (en) Method of diagnosis, prognostic or treatment of neurodegenerative diseases
EP2734221A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE BY ADMINISTRATION OF AN ANGIOGENIC MEDIUM
WO2012151464A3 (en) Use of radiographic contrast agents for detecting dental caries
WO2012174243A8 (en) D -serine for the treatment of visual system disorders
BR112013026868A2 (pt) intermediário para a síntese de caspofungina e método para o seu preparo

Legal Events

Date Code Title Description
FG Grant or registration